Composition containing sulfonylureas sugar-reducing drug and statins lipid-lowering drug

A composition and technology of sulfonylureas, applied in the field of pharmacy, can solve the problem that there is no effective drug and solution for the treatment and prevention of diabetes with lipid disorder, so as to reduce the incidence of cardiovascular accidents and death rates, Strong selectivity and definite curative effect

Inactive Publication Date: 2008-01-16
BEIJING HUAANFO BIOMEDICAL RES CENT
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There has been no report on the prevention and treatment of diabetes associated with lipid disorders, and the clinical combination of drugs is mostly limited to the combination of drugs when diabetic patients are accompanied by hyperlipidemia. There is no effective drug and program for the treatment and prevention of diabetes associated with lipid disorders

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0029] Example 1 Preparation of Compound Glimepiride Pitavastatin Calcium Tablets (1000 Tablets)

[0030] formula:

[0031] Glimepiride 1.0g

[0032] Pitavastatin Calcium 1.0g

[0033] Calcium hydrogen phosphate 40.0g

[0034] Lactose 50.0g

[0035] Low-substituted hydroxypropyl cellulose 20.0g

[0036] Carboxymethyl starch sodium 10.0g

[0037] Proper amount of povidone K30 aqueous solution

[0038] Magnesium Stearate 1.3g

[0039]

[0040] Makes 1000 pieces

[0041] Preparation:

[0042] 1) Take the prescribed amount of glimepiride, pitavastatin calcium, carboxymethyl starch sodium and low-substituted hydroxypropyl cellulose, pass through a 100-mesh sieve, and mix uniformly by the method of equal increments to obtain powder A, which is set aside.

[0043] 2) Dibasic calcium phosphate and lactose were passed through a 100-mesh sieve and dried at 75°C for 2 hours.

[0044] 3) Mix the powder A obtained in 1) with the mixed calcium...

Embodiment 2

[0050] Example 2 Preparation of Compound Glimepiride Pitavastatin Calcium Tablets (1000 Tablets)

[0051] formula:

[0052] Glimepiride 2.0g

[0053] Pitavastatin Calcium 1.0g

[0054] Calcium hydrogen phosphate 40.0g

[0055] Lactose 50.0g

[0056] Low-substituted hydroxypropyl cellulose 20.0g

[0057] Carboxymethyl starch sodium 10.0g

[0058] Proper amount of povidone K30 aqueous solution

[0059] Magnesium Stearate 1.3g

[0060]

[0061] Makes 1000 pieces

[0062] The preparation method is the same as in Example 1, and each tablet contains 1 mg of pitavastatin calcium and 2 mg of glimepiride in the prepared compound tablet, and the mass ratio thereof is 1.2.

Embodiment 3

[0063] Example 3 Preparation of Compound Glipizide Pitavastatin Calcium Tablets (1000 Tablets)

[0064] formula:

[0065] Glipizide 2.5g

[0066] Pitavastatin Calcium 1.0g

[0067] Calcium hydrogen phosphate 40.0g

[0068] Lactose 50.0g

[0069] Low-substituted hydroxypropyl cellulose 20.0g

[0070] Carboxymethyl starch sodium 10.0g

[0071] Proper amount of povidone K30 aqueous solution

[0072] Magnesium Stearate 1.3g

[0073]

[0074] Makes 1000 pieces

[0075] The preparation method was the same as in Example 1, and each of the prepared compound tablets contained 2.5 mg of glipizide and 1.0 mg of pitavastatin calcium, and the mass ratio thereof was 2.5:1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to view more

Abstract

The invention relates to a compound of sulfaurea drug and statins lipid lowering drug, belonging to the pharmaceutical field. The compound contains sulfaurea drug of therapy dose or salts of the sulfaurea, statins lipid lowering drug with low therapy dose or the pharmaceutical salt and pharmaceutical carrier or excipient. The invention also relates to the purpose of the compound in preparation of drug for preventing and treating a living body ill with diabetes and lipid metabolism disorder, providing an effective therapeutic schedule for the diabetes and lipid metabolism disorder.

Description

technical field [0001] The present invention relates to a composition containing sulfonylurea hypoglycemic drugs and statin hypolipidemic drugs, and the use of the composition in the preparation of drugs for the prevention and treatment of living organisms with diabetes and lipid disorders, belonging to field of pharmacy. Background technique [0002] Epidemiological studies have found that compared with non-diabetic patients, the risk of cardiovascular disease mortality in patients with type 2 diabetes increases 2-6 times, and coronary heart disease (CHD) is the main cause of death in patients with type 2 diabetes, at least 50% of patients Died of CHD. The relative risk of CHD death in male patients with type 2 diabetes is 1.5% to 2.5%, and that in female is 1.7% to 4%. Many factors can increase the incidence of CHD in type 2 diabetes, but many evidences show that abnormal blood lipid levels and abnormal lipid metabolism are the most important risk factors. The risk of d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/64A61K31/47A61K31/351A61K9/20A61K9/48A61K9/08A61K47/38A61P3/10A61P3/06
Inventor 戴成祥李晓涛陈明侠于多王燕王文艳
Owner BEIJING HUAANFO BIOMEDICAL RES CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap